EA039764B1 - Соль n-(2,6-диэтилфенил)-8-({4-[4-(диметиламино)пиперидин-1-ил]-2-метоксифенил}амино)-1-метил-4,5-дигидро-1h-пиразоло[4,3-h]хиназолин-3-карбоксамида, ее получение и препараты, которые ее содержат - Google Patents
Соль n-(2,6-диэтилфенил)-8-({4-[4-(диметиламино)пиперидин-1-ил]-2-метоксифенил}амино)-1-метил-4,5-дигидро-1h-пиразоло[4,3-h]хиназолин-3-карбоксамида, ее получение и препараты, которые ее содержат Download PDFInfo
- Publication number
- EA039764B1 EA039764B1 EA202090115A EA202090115A EA039764B1 EA 039764 B1 EA039764 B1 EA 039764B1 EA 202090115 A EA202090115 A EA 202090115A EA 202090115 A EA202090115 A EA 202090115A EA 039764 B1 EA039764 B1 EA 039764B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- quinazoline
- pyrazolo
- amino
- dimethylamino
- piperidin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17305826 | 2017-06-29 | ||
| PCT/EP2018/067394 WO2019002454A1 (en) | 2017-06-29 | 2018-06-28 | NOVEL N- (2,6-DIETHYLPHENYL) -8 - ({4- [4- (DIMETHYLAMINO) PIPERIDIN-1-YL] -2-METHOXYPHENYL} AMINO) -1-METHYL-4,5-DIHYDRO-1H SALT -PYRAZOLO [4,3-H] QUINAZOLINE-3-CARBOXAMIDE, ITS PREPARATION AND FORMULATIONS CONTAINING THE SAME |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA202090115A1 EA202090115A1 (ru) | 2020-05-25 |
| EA039764B1 true EA039764B1 (ru) | 2022-03-11 |
Family
ID=59313166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202090115A EA039764B1 (ru) | 2017-06-29 | 2018-06-28 | Соль n-(2,6-диэтилфенил)-8-({4-[4-(диметиламино)пиперидин-1-ил]-2-метоксифенил}амино)-1-метил-4,5-дигидро-1h-пиразоло[4,3-h]хиназолин-3-карбоксамида, ее получение и препараты, которые ее содержат |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US11160806B2 (enExample) |
| EP (1) | EP3645535B1 (enExample) |
| JP (1) | JP7141416B2 (enExample) |
| KR (1) | KR102609333B1 (enExample) |
| CN (1) | CN110896636B (enExample) |
| AR (1) | AR112040A1 (enExample) |
| AU (1) | AU2018293729B9 (enExample) |
| CA (1) | CA3068357C (enExample) |
| CL (1) | CL2019003848A1 (enExample) |
| EA (1) | EA039764B1 (enExample) |
| ES (1) | ES2900048T3 (enExample) |
| IL (1) | IL271628B2 (enExample) |
| MA (1) | MA49498A (enExample) |
| PL (1) | PL3645535T3 (enExample) |
| PY (1) | PY1850855A (enExample) |
| SG (1) | SG11201912651WA (enExample) |
| TW (1) | TWI750393B (enExample) |
| UY (1) | UY37778A (enExample) |
| WO (1) | WO2019002454A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025002962A1 (en) | 2023-06-30 | 2025-01-02 | Nerviano Medical Sciences S.R.L. | Use of a mps1 inhibitor for the treatment of hepatocellular carcinoma |
| WO2025021587A1 (en) | 2023-07-21 | 2025-01-30 | Nerviano Medical Sciences S.R.L. | Combination of a mps1 inhibitor and immune checkpoint inhibitors, uses and pharmaceutical compositions thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2303891A1 (en) * | 2008-06-26 | 2011-04-06 | Nerviano Medical Sciences S.r.l. | Pyrazolo-quinazolines |
-
2018
- 2018-06-21 UY UY0001037778A patent/UY37778A/es not_active Application Discontinuation
- 2018-06-28 JP JP2019572116A patent/JP7141416B2/ja active Active
- 2018-06-28 ES ES18732820T patent/ES2900048T3/es active Active
- 2018-06-28 WO PCT/EP2018/067394 patent/WO2019002454A1/en not_active Ceased
- 2018-06-28 CA CA3068357A patent/CA3068357C/en active Active
- 2018-06-28 EP EP18732820.8A patent/EP3645535B1/en active Active
- 2018-06-28 AU AU2018293729A patent/AU2018293729B9/en active Active
- 2018-06-28 EA EA202090115A patent/EA039764B1/ru unknown
- 2018-06-28 TW TW107122235A patent/TWI750393B/zh active
- 2018-06-28 CN CN201880043442.0A patent/CN110896636B/zh active Active
- 2018-06-28 SG SG11201912651WA patent/SG11201912651WA/en unknown
- 2018-06-28 AR ARP180101781A patent/AR112040A1/es unknown
- 2018-06-28 PL PL18732820T patent/PL3645535T3/pl unknown
- 2018-06-28 PY PY201801850855A patent/PY1850855A/es unknown
- 2018-06-28 MA MA049498A patent/MA49498A/fr unknown
- 2018-06-28 US US16/624,488 patent/US11160806B2/en active Active
- 2018-06-28 KR KR1020207002339A patent/KR102609333B1/ko active Active
-
2019
- 2019-12-22 IL IL271628A patent/IL271628B2/en unknown
- 2019-12-26 CL CL2019003848A patent/CL2019003848A1/es unknown
-
2021
- 2021-09-30 US US17/490,318 patent/US20220016122A1/en not_active Abandoned
-
2024
- 2024-07-01 US US18/760,494 patent/US20240350501A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2303891A1 (en) * | 2008-06-26 | 2011-04-06 | Nerviano Medical Sciences S.r.l. | Pyrazolo-quinazolines |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2900048T3 (es) | 2022-03-15 |
| MA49498A (fr) | 2021-05-26 |
| US11160806B2 (en) | 2021-11-02 |
| KR20200020905A (ko) | 2020-02-26 |
| IL271628B1 (en) | 2023-03-01 |
| AU2018293729B9 (en) | 2022-07-14 |
| UY37778A (es) | 2019-01-31 |
| US20220016122A1 (en) | 2022-01-20 |
| CN110896636A (zh) | 2020-03-20 |
| SG11201912651WA (en) | 2020-01-30 |
| EA202090115A1 (ru) | 2020-05-25 |
| KR102609333B1 (ko) | 2023-12-01 |
| EP3645535B1 (en) | 2021-09-08 |
| PY1850855A (es) | 2019-04-01 |
| TW201904971A (zh) | 2019-02-01 |
| US20240350501A1 (en) | 2024-10-24 |
| JP2020525477A (ja) | 2020-08-27 |
| CN110896636B (zh) | 2022-07-19 |
| CL2019003848A1 (es) | 2020-07-10 |
| IL271628B2 (en) | 2023-07-01 |
| US20200246339A1 (en) | 2020-08-06 |
| EP3645535A1 (en) | 2020-05-06 |
| AU2018293729B2 (en) | 2022-03-10 |
| CA3068357A1 (en) | 2019-01-03 |
| WO2019002454A1 (en) | 2019-01-03 |
| PL3645535T3 (pl) | 2022-03-21 |
| TWI750393B (zh) | 2021-12-21 |
| AR112040A1 (es) | 2019-09-11 |
| CA3068357C (en) | 2022-04-19 |
| JP7141416B2 (ja) | 2022-09-22 |
| AU2018293729A1 (en) | 2020-01-23 |
| BR112019027924A2 (pt) | 2020-08-18 |
| IL271628A (en) | 2020-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5851990B2 (ja) | Ｐｌｋ阻害剤の塩 | |
| CN111148745A (zh) | Fgfr抑制剂的结晶形式及其制备方法 | |
| KR20170032330A (ko) | Ｃ-Ｍｅｔ 억제제의 결정질 유리 염기 또는 이의 결정질 산 염, 및 이들의 제조방법 및 용도 | |
| CN103282365B (zh) | 结晶的(8S,9R)‑5‑氟‑8‑(4‑氟苯基)‑9‑(1‑甲基‑1H‑1,2,4‑三唑‑5‑基)‑8,9‑二氢‑2H‑吡啶并[4,3,2‑de]酞嗪‑3(7H)‑酮甲苯磺酸盐 | |
| US20240350501A1 (en) | SALT OF N-(2,6-DIETHYLPHENYL)-8-({4-[4-(DIMETHYLAMINO) PIPERIDIN-1-YL]-2-METHOXYPHENYL}AMINO)-1-METHYL-4,5-DIHYDRO-1H-PYRAZOLO[4,3-h]QUINAZOLINE-3-CARBOXAMIDE, ITS PREPARATION, AND FORMULATIONS CONTAINING IT | |
| AU2019218186B2 (en) | Urea-substituted aromatic ring-linked dioxinoquinoline compounds, preparation method and uses thereof | |
| CN120379987A (zh) | 嘧啶化合物的新型晶型和包含其的药物组合物以及其使用方法 | |
| EP3077392B1 (en) | Crystalline forms of n-(4-((3-(2-amino-4-pyrimidinyl) - 2-pyridinyl)oxy)phenyl)-4-(4-methyl - 2-thienyl)-1-phthalazinamine pharmaceutically acceptable salts and uses thereof | |
| TW202023562A (zh) | 喹唑啉化合物及其鹽酸鹽之結晶形態 | |
| KR20210024004A (ko) | Cdk4/6의 활성을 억제하기 위한 화합물의 결정 형태 및 그것의 용도 | |
| WO2024235289A1 (zh) | 用于egfr蛋白降解的化合物及其用途 | |
| WO2023093859A1 (zh) | Axl激酶抑制剂的盐、其制备方法和用途 | |
| EP3750894B1 (en) | Urea-substituted aromatic ring-linked dioxazoline compound, preparation method therefor, and uses thereof | |
| HK40022862A (en) | Salt of a compound inhibiting mps1 kinase, its preparation and formulations containing it | |
| HK40022862B (en) | Salt of a compound inhibiting mps1 kinase, its preparation and formulations containing it | |
| BR112019027924B1 (pt) | Fosfato de n-(2,6-dietilfenil)-8-({4-[4-(dimetilamino)piperidin-1-il]-2- metoxifenil}amino)-1-metil-4,5-di-hidro-1h-pirazolo[4,3-h]quinazolina-3- carboxamida, processo para a sua obtenção, composição farmacêutica, combinação e seus usos | |
| HK40003818A (en) | Polymorphs of gdc-0032, methods of production, and pharmaceutical uses thereof | |
| HK1223101A1 (zh) | Gdc-0032的多晶型物、其制备方法和药物用途 |